½ÃÀ庸°í¼­
»óǰÄÚµå
1544666

¼¼°èÀÇ È¨ÄÉ¾î °Ë»ç ½ÃÀå - ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®°ú ¿¹Ãø(2024-2032³â)

Home Care Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ȨÄÉ¾î °Ë»ç ½ÃÀå ±Ô¸ð´Â Á¦Ç° ¹ßÇ¥ÀÇ ±ÞÁõ°ú °Ç°­ ¿ëµµ°úÀÇ ÅëÇÕÀ¸·Î 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 6.8%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ±â¾÷Àº ´Ù¾çÇÑ °Ç°­ ¿ëµµ°ú ¿øÈ°ÇÏ°Ô Çù·ÂÇÏ´Â »õ·Î¿î °¡Á¤¿ë °Ë»ç Àåºñ¸¦ ¹ßÇ¥Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû Áøº¸¸¦ ÅëÇØ °³ÀÎÀº Áý¿¡ ¸Ó¹«¸£¸é¼­ º¸´Ù ½±°í Á¤È®ÇÏ°Ô °Ç°­ »óŸ¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ½Ç½Ã°£ °Ç°­ ÃßÀûÀ» ¿ëÀÌÇÏ°Ô ÇÒ »Ó¸¸ ¾Æ´Ï¶ó °³ÀÎÈ­ Äɾî·ÎÀÇ ±æÀ» ¿­¾î, ÀÌ ºÐ¾ßÀÇ Ãß°¡ Çõ½Å°ú º¸±Þ¿¡ ¹ÚÂ÷¸¦ °¡ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 10¿ù, PHASE Scientific Americas´Â µðÁöÅÐ °Ç°­ Ç÷§Æû°ú °áÇÕµÈ INDICAID Health(TM) °¡Á¤¿ë °Ë»ç ŰƮ¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ÃֽŠÁ¦Ç°Àº µðÁöÅÐ µµ±¸¿Í ÅëÇÕÇϵµ·Ï ¼³°èµÇ¾úÀ¸¸ç »ç¿ëÀÚ´Â Áý¿¡¼­ È¿À²ÀûÀ¸·Î °Ë»ç¸¦ ½Ç½ÃÇÏ°í °Ç°­À» °ü¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¦Ç° À¯Çüº°·Î 2024³âºÎÅÍ 2032³â »çÀÌ¿¡ Á¡°Ë ÆÐ³Î ºÎ¹®¿¡ ÀÇÇÑ È¨ÄÉ¾î °Ë»ç ½ÃÀå °¡Ä¡´Â »ó´çÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ·¯ÇÑ ±ÞÁõÀº ´Ù¾çÇÑ °Ç°­ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ÀÌ¿¡ ´ëÀÀÇϱâ À§ÇØ °¢ ȸ»ç´Â °í±Þ °Ë»ç ÆÐ³ÎÀ» °³¹ßÇÏ¿© °³ÀÎÀÌ Áý¿¡¼­ ´Ù¾çÇÑ Áø´ÜÀ» ÇÒ ¼ö ÀÖµµ·ÏÇϰí ÀÖ½À´Ï´Ù. ¿©·¯ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °­È­ÇÑ ÀÌ °Ë»ç ÆÐ³ÎÀº Àü¹ÝÀûÀÎ °Ç°­ ÅëÂû·ÂÀ» Á¦°øÇÏ¿© »ç¿ëÀÚÀÇ »óÅ ¸ð´ÏÅ͸µ°ú °Ç°­ ÃßÀûÀ» °£¼ÒÈ­ÇÕ´Ï´Ù.

¿Â¶óÀÎ ¾à±¹ À¯Åë ä³ÎÀ» ÅëÇÑ È¨ÄÉ¾î °Ë»ç ¾÷°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö »ó´çÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ »ó½ÂÀº ¼ÒºñÀÚµéÀÌ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ´Â °Í¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í Àֱ⠶§¹®ÀÔ´Ï´Ù. À¯ÅëÀÇ µðÁöÅÐ ½ÃÇÁÆ®´Â ȨÄÉ¾î °Ë»ç Á¦Ç°ÀÇ ÀÔ¼ö¸¦ °£¼ÒÈ­ÇÒ »Ó¸¸ ¾Æ´Ï¶ó, »ç¿ëÀÚÀÇ Æí¸®¼º°ú È¿À²¼ºÀ» ³ôÀÔ´Ï´Ù. ¾×¼¼½º¸¦ ´õ¿í °­È­Çϱâ À§ÇØ ¿Â¶óÀÎ ¾à±¹Àº ½Ç½Ã°£ Àç°í ¾÷µ¥ÀÌÆ®, °³º°È­µÈ Ãßõ, Á÷Á¢ ¹è´Þ µîÀÇ ±â´ÉÀ» äÅÃÇÕ´Ï´Ù.

Áö¿ªº°·Î´Â À¯·´ÀÇ È¨ÄÉ¾î °Ë»ç ½ÃÀå ±Ô¸ð´Â °í·ÉÈ­¿Í ¸¸¼º Áúȯ Áõ°¡¸¦ ¹è°æÀ¸·Î, 2024³âºÎÅÍ 2032³â¿¡ °ÉÃÄ ÇöÀúÇÑ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÌ ¸¸¿¬ÇÔ¿¡ µû¶ó Á¤±âÀûÀÎ ÀçÅà °Ë»ç ¹× °ü¸® ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ ´ëÀÀÇϱâ À§ÇØ °¢ ȸ»ç´Â ȨÄÉ¾î °Ë»ç Á¦Ç°À» ¹Ì¼¼ Á¶Á¤ÇÏ°í »ç¿ëÀÚ°¡ Æí¾ÈÇÏ°Ô °Ç°­ »óŸ¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖµµ·Ï ÇÊ¿äÇÑ µµ±¸¸¦ È®º¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤±³ÇÑ °Ë»ç ±â¼ú°ú µðÁöÅÐ °Ç°­ Ç÷§Æû°úÀÇ ÅëÇÕ °­È­¿Í °°Àº ¹ßÀüÀ¸·Î ÀÌ Áö¿ªÀÇ °³ÀεéÀº º¸´Ù Àû±ØÀûÀ¸·Î °Ç°­À» °ü¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¸¸¼º Áúȯ Áõ°¡
      • Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • Á¦Ç°ÀÇ ±â¼úÀû Áøº¸
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè ¹× °úÁ¦
      • °íºñ¿ë
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • °¡°Ý ºÐ¼®, 2023³â
  • ±â¼úÀû Àü¸Á
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • °¸ ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߰衤¿¹Ãø : Á¦Ç° À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ½ºÆ®¸³
  • Ä«¼¼Æ®
  • Å×½ºÆ® ÆÐ³Î
  • ¹Ìµå ½ºÆ®¸²
  • µö Ä«µå
  • ±âŸ Á¦Ç° À¯Çü

Á¦6Àå ½ÃÀå Ã߰衤¿¹Ãø : °Ë»ç À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • °¨¿°Áõ
  • ´ç´¢º´ ¹× Æ÷µµ´ç
  • HIV
  • ÀÓ½Å
  • ÄÝ·¹½ºÅ׷Ѱú Áß¼ºÁö¹æ
  • ¿ä·Î °¨¿°Áõ
  • ±âŸ °Ë»ç À¯Çü

Á¦7Àå ½ÃÀå Ã߰衤¿¹Ãø : »ùÇú°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • Ç÷¾×
  • ¼Òº¯
  • Ÿ¾×
  • ±âŸ »ùÇÃ

Á¦8Àå ½ÃÀå Ã߰衤¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¼Ò¸Å ¾à±¹
  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ±âŸ À¯Åë ä³Î

Á¦9Àå ½ÃÀå Ã߰衤¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Abbott
  • ACON Laboratories, Inc.
  • Ascensia Diabetes Care Holdings AG
  • BD
  • bioLytical Laboratories Inc.
  • BioSure
  • Cardinal Health
  • Chembio Diagnostics, Inc
  • F. Hoffmann-La Roche Ltd.
  • LifeScan IP Holdings, LLC
  • MP BIOMEDICALS
  • Nova Biomedical
  • OraSure Technologies, Inc.
  • Quidel Corp.
  • SA Scientific Ltd
  • Siemens Healthcare GmbH
  • Sterilab Services
JHS 24.10.04

Home Care Testing Market size is projected to expand at a 6.8% CAGR from 2024 to 2032, due to the surge in product launches and their integration with health applications.

In response to the rising demands, companies are unveiling new home testing devices that seamlessly interface with various health applications. These technological strides empower individuals to monitor their health with greater ease and precision, all from the comfort of their homes. Such advancements not only facilitate real-time health tracking but also pave the way for personalized care, spurring further innovation and adoption in the sector. For instance, in October 2023, PHASE Scientific Americas rolled out the INDICAID Health(TM) at-home test kits, coupled with a digital health platform. This latest offering, designed to integrate with digital tools, empowers users to efficiently conduct tests and manage their health from home.

The overall market is segregated into product type, test type, sample, distribution channel, and region.

Based on product type, the home care testing market value from the test panel segment is estimated to rise at a substantial rate from 2024 to 2032. This surge is attributed to the rising demand for diverse health solutions. In response, companies are crafting advanced test panels, allowing individuals to conduct a wide array of diagnostics from home. These test panels, enriched with multiple biomarkers, offer holistic health insights, simplifying condition monitoring and wellness tracking for users.

Home care testing industry size from the online pharmacies distribution channel segment is anticipated to grow at a substantial CAGR through 2032. This uptick is largely due to the increasing demand for easy consumer access. The digital shift in distribution not only simplifies the acquisition of home care testing products but also enhances user convenience and efficiency. To further bolster accessibility, online pharmacies are adopting features like real-time inventory updates, personalized recommendations, and direct-to-door delivery.

Regionally, the Europe home care testing market size is projected to depict a notable CAGR between 2024 and 2032, on account of the aging population and the rise in chronic diseases. As chronic conditions become more prevalent, there is a heightened demand for regular at-home testing and management. In response, companies are fine-tuning their home care testing products, ensuring users have the tools they need for effortless health monitoring. Furthermore, with advancements like sophisticated testing technologies and enhanced integration with digital health platforms, individuals in the region are better equipped to manage their health proactively.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic diseases
      • 3.2.1.2 Growing demand for point of care testing
      • 3.2.1.3 Technological advancements in the products
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High costs
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pricing analysis, 2023
  • 3.6 Technological landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Future market trends
  • 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Strip
  • 5.3 Cassette
  • 5.4 Test panel
  • 5.5 Midstream
  • 5.6 Dip card
  • 5.7 Other product types

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Infectious disease
  • 6.3 Diabetes and glucose
  • 6.4 HIV
  • 6.5 Pregnancy
  • 6.6 Cholesterol and triglycerides
  • 6.7 Urinary tract infection
  • 6.8 Other test types

Chapter 7 Market Estimates and Forecast, By Sample, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Blood
  • 7.3 Urine
  • 7.4 Saliva
  • 7.5 Other samples

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Retail pharmacies
  • 8.3 Hospital pharmacies
  • 8.4 Online pharmacies
  • 8.5 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott
  • 10.2 ACON Laboratories, Inc.
  • 10.3 Ascensia Diabetes Care Holdings AG
  • 10.4 BD
  • 10.5 bioLytical Laboratories Inc.
  • 10.6 BioSure
  • 10.7 Cardinal Health
  • 10.8 Chembio Diagnostics, Inc
  • 10.9 F. Hoffmann-La Roche Ltd.
  • 10.10 LifeScan IP Holdings, LLC
  • 10.11 MP BIOMEDICALS
  • 10.12 Nova Biomedical
  • 10.13 OraSure Technologies, Inc.
  • 10.14 Quidel Corp.
  • 10.15 SA Scientific Ltd
  • 10.16 Siemens Healthcare GmbH
  • 10.17 Sterilab Services
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦